CLAIMS

1. A pharmaceutical composition comprising one or more pharmaceutically acceptable excipients, carriers, and/or diluents and one or more non-steroidal anti-inflammatory drugs (NSAID), wherein the total concentration of NSAIDs is less than 75 mg/ml,

wherein more than 90% of the one or more NSAIDs is acetylsalicylic acid by weight of the NSAIDs in the composition and the total weight of said one or more NSAIDs is less than 50 mg.

2. The pharmaceutical composition according to claim 1, wherein said NSAIDs comprise acetylsalicylic acid (ASA).

3. The pharmaceutical composition according to claim 2, wherein the concentration of said acetylsalicylic acid is less than 10 mg/ml.

4. The pharmaceutical composition according to any one of claims 1-3, wherein said total concentration of NSAIDs is less than 20 mg/ml.

5. The pharmaceutical composition according to any one of claims 1-4, wherein the total NSAID content of said composition is more than 90% or more than 95% or more than 99% salicylate and derivatives thereof (*e.g.*, acetylsalicylic acid, salicylic acid) by weight of the NSAID content.

6. The pharmaceutical composition according to any one of claims 1-4, wherein acetylsalicylic acid is the only NSAID in said composition or more than 95% or more than 99% of the NSAIDs is acetylsalicylic acid by weight of the NSAIDs in the composition.

7. The pharmaceutical composition according to any one of claims 1-4, wherein acetylsalicylic acid and aloe extract are the only NSAIDs in said composition or more than 90% or more than 95% or more than 99% of the NSAIDs is acetylsalicylic acid and aloe extract by weight of the NSAIDs in the composition.

8. The pharmaceutical composition according to any one of claims 1-7, further comprising lactoferrin and lysozyme.

9. The pharmaceutical composition according to claim 8, wherein the weight ratio of said lactoferrin to lysozyme is 1:1 to 1:100.

10. The pharmaceutical composition according to claim 8 or 9, wherein the weight ratio of lactoferrin and lysozyme to NSAID is from 10:1 to 1:10.

11. The pharmaceutical composition according to any one of claims 1-10, wherein said pharmaceutical composition does not comprise a corticosteroid.

12. The pharmaceutical composition according to any one of claims 1-11, wherein said pharmaceutical composition comprises:

a) from 1 to 10 mg/ml of said one or more NSAIDs;

b) from 0.1 to 1 mg/ml of lactoferrin;

c) from 1 to 10 mg/ml of lysozyme;

c) from 10 to 100 mg/ml of glycerol;

e) from 100 to 400 mg/ml of sweetener;

f) from 1 to 20 mg/ml menthol;

g) from 1 to 20 mg/ml carboxymethyl cellulose; and

h) from 1 to 20 mg/ml aloe.

13. The pharmaceutical composition according to any one of claims 1-12, wherein said pharmaceutical composition is formulated as a lozenge.

14. The pharmaceutical composition according to claim 13, wherein the total weight of said one or more NSAIDs is less than 25 mg, less than 20 mg, or less than 10 mg.

15. The pharmaceutical composition according to claim 13, wherein said lozenge comprises from 0.1 to 10 mg of acetylsalicylic acid.

16. The pharmaceutical composition according to claim 13, wherein said lozenge comprises from 0.1 to 10 mg of acetylsalicylic acid and more than 90% of said one or more NSAIDs is acetylsalicylic acid by weight of the NSAIDs.

17. The pharmaceutical composition according to any one of claims 13-16, wherein said lozenge comprises:

a) from 1 to 10 mg of said one or more NSAIDs;

b) from 0.1 to 1 mg of lactoferrin;

c) from 1 to 10 mg of lysozyme;

c) from 10 to 100 mg of glycerol;

e) from 100 to 400 mg of sweetener;

f) from 1 to 20 mg menthol;

g) from 1 to 20 mg carboxymethyl cellulose; and

h) from 1 to 20 mg aloe.

18. The pharmaceutical composition according to any one of claims 1-12, wherein said pharmaceutical composition is formulated as an oral spray.

19. Use of a pharmaceutical composition according to any one of claims 1-18 in the manufacture of a medicament for the treatment or prophylaxis of sore throat in a subject.

20. The use according to claim 19, wherein less than 325 mg (*e.g.*, less than 100 mg, less than 75 mg, less than 50 mg, less than 25 mg, less than 20 mg, less than 15 mg) of the plurality of NSAIDs are to be administered in 24 hours.

21. The use according to claim 19, wherein less than 325 mg (*e.g.*, less than 100 mg, less than 75 mg, less than 50 mg, less than 25 mg, less than 20 mg, less than 15 mg) of the plurality of NSAIDs are to be administered in 12 hours.

22. The use according to any one of claims 19-21, wherein said sore throat is associated with inflammation resulting in increased prostaglandin production.

23. A pharmaceutical product comprising:

(a) a body configured to be inserted into an oral passage for dispensing the oral spray composition according to claim 18;

(b) a reservoir in fluid communication with said orifice, wherein said oral spray composition is contained in said reservoir;

(c) a pump mechanism capable of expelling said oral spray composition through said orifice in appropriate sized aerosolized droplets; capable of coating the oral mucosa (*e.g.* mucosa of the throat) of a user.

24. The pharmaceutical product according to claim 23, wherein said pump mechanism is configured to expel from 100 μL to 1000 μL of said oral spray composition.

25. Use of the pharmaceutical product according to claim 23 or 24 in the manufacture of a medicament for the treatment or prophylaxis of sore throat in a subject in need thereof:

a) wherein a portion of the pharmaceutical product according to claim 23 or 24 is configured to be inserted into an oral passage into the oral passage of said subject; and

b) wherein said oral spray is to be administered to said subject by actuating said pump mechanism is.

26. The use according to claim 25, wherein said inserting and actuating steps are repeated at a time point more than 10 minutes after the previous of said administration oral spray composition.

27. Use of a plurality of NSAIDs in the manufacture of a medicament for the treatment of sore throat in a subject in need thereof, wherein less than 75 mg (*e.g.*, less than 50 mg, less than 25 mg, less than 15 mg) of said plurality of NSAIDs is to be administered to said throat, wherein more than 90% of said plurality of NSAIDs is acetylsalicylic acid by weight of said plurality of NSAIDs.

28. The use according to claim 27, wherein less than 325 mg (*e.g.*, less than 100 mg, less than 75 mg, less than 50 mg, less than 25 mg, less than 20 mg, less than 15 mg) of said plurality of NSAIDs are to be administered in 24 hours.

29. The use according to claim 27, wherein less than 325 mg (*e.g.*, less than 100 mg, less than 75 mg, less than 50 mg, less than 25 mg, less than 20 mg, less than 15 mg) of said plurality of NSAIDs are to be administered in 12 hours.

30. The use according to any one of claims 19-22, and 25-29, wherein said administration has minimal or no effect on the barrier integrity of the mucosa (*e.g.*, as measured by TEER) as compared to an otherwise identical mucosa that had not been administered said one or more NSAIDs.